Barclays Maintains an 'Overweight' on Agilent (A); LSG - The Next Leg Of The Agilent Story

Barclays maintains an 'Overweight' on Agilent (NYSE: A), PT $54.

Barclays analyst says, "We will be hosting a conference call on June 3rd with CFO Didier Hirsch and Nick Roelofs, Ph.D., President of Agilent's Life Sciences Group (LSG). Though LSG today accounts for just ~20% of Agilent's sales, it is a major area of investment for the company. LSG represents Agilent's most under-penetrated, yet largest and fastest growing market opportunity."

"Agilent, along with Waters (NYSE: WAT), has been our top Tools pick this year. Agilent has plenty of room to run, in our opinion, with above-peer revenue & earnings growth (with Agilent's recently updated operating model) and a strong financial position justifying the premium multiple. Manufacturing leadership & a strong China footprint will be a differentiator, with additional upside from the Varian deal."

For more ratings news on Agilent click here and for the rating history of Agilent click here.

Shares of Agilent closed at $50.03 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week
• CoStar Group acquires Zonda for $800M, adding new home data